Marshall S. Stanton sold $743k of AORT
SVP, Clinical & MD Affair at ARTIVION, INC.. 26,132 shares at an average of $28.44, traded Jun 13, 2025, filed Jun 16, 2025.
Score components
- +15RoleOfficer
- +21Trade size$743k at market
- +5Share of holdings soldSold 25% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000784199-25-000131, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 13, 2025 | SOpen-market sale Common Stock10b5-1 | -8,747 | $28.46 | $249k | 96,585 | Jun 16, 2025 |
| Jun 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,253 | $28.47 | $36k | 95,332 | Jun 16, 2025 |
| Jun 13, 2025 | SOpen-market sale Common Stock10b5-1 | -14,306 | $28.42 | $407k | 81,026 | Jun 16, 2025 |
| Jun 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,826 | $28.43 | $52k | 79,200 | Jun 16, 2025 |
Related signals
Other insiders at ARTIVION, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $287k 11,480 shares | -22% | |
| 32Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $216k 8,003 shares | -13% | |
| 17Weak | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $443k 15,000 shares | -19% | |
| 38Weak | ARTIVION, INC. | Anthony B. Semedo director | $74k 2,600 shares | -7% | |
| 36Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $254k 8,748 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $288k 9,926 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $307k 10,548 shares | -9% | |
| 10Weak | ARTIVION, INC. | John E Davis Chief Commercial Officer | $357k 15,100 shares | -7% | |
| 12Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $426k 18,020 shares | -8% | |
| 37Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $53k 2,124 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.